$ 535.04
Details
The 1A29 antibody reacts with ICAM-1 (CD54), an 85kDa surface glycoprotein expressed on vascular endothelium in lymphoid tissues, thymic stromal cells, peripheral blood monocytes, peritoneal macrophages and mast cells, dendritic cells, and weakly on peripheral lymphocytes and thymocytes. ICAM-1 is a ligand for LFA-1 (CD11a/CD18) and Mac-1 (CD11b/CD18). Its expression is upregulated on activated lymphocytes and endothelial cells. 1A29 mAb inhibits PMA-induced aggregation of PHA-stimulated splenic blasts, as well as the adhesion of mitogen-stimulated blasts to HEV-derived endothelial cells and purified ICAM-1. It has also been reported that 1A29 antibody can inhibit leukocyte infiltration in in vivo systems, blocks induction of experimental allergic encephalomyelitis, and reduces NK-cell adhesion to tumor cells. The effects of in vivo administration of the 1A29 monoclonal antibody have been thoroughly investigated.
